Stakeholder Insight: Neuropathic Low Back Pain - Off-label Revenue Despite Diagnostic Challenge

Questions: Discounts, Updates etc.

Price: $13,600.00

Publication Date: 2004-06-03

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Despite millions of patients worldwide, not one neuropathic pain drug company is prioritizing the neuropathic low back pain (NLBP) market. The problem is simply that this patient group is difficult to define in clinical practice. Once diagnosis is made, however, physicians commonly prescribe recognized neuropathic pain drugs, thus NLBP offers a significant source of off-label drug sales in the US.


Scope

  • Quantitative treatment data from over 384 physicians from the US, Japan, France, Germany, Italy, Spain, and the UK
  • Analysis of epidemiology, assessment and referral patterns, and first- to third-line treatments
  • Discussion of the market need for more evidence-based treatments, improved diagnosis and identification of treatment responders
  • Coverage of the hot topics including the use of opioids, the upcoming launch of pregabalin


    • Report Highlights
    Neuropathic low back pain affects an estimated 5.6 million people in the US alone. However, this type of back pain is rarely diagnosed and is poorly treated in the primary care setting. As such, there is strong need to educate physicians, especially PCPs, about the difference between the types of low back pain.

    There is little consensus as to best treatment practice between countries and even between physician types, which is compounded by the heterogeneity of patients and a dearth of randomized controlled trial data. A company can grow its share of the market by providing clear, convincing scientific data as either monotherapy or combination.

    The future market is not entirely the reserve of generic companies and Pfizer. A significant commercial opportunity exists for medical device companies, although the biggest challenge is to change the physician perception that interventional treatment of NLBP is a modestly effective 'last resort'.


    Reasons to Purchase

  • Forecast product sales by understanding key aspects of NLBP epidemiology, referral, diagnosis, treatment, and unmet needs
  • Improve pain product positioning strategies by identifying the commercial opportunities offered by the NLBP niche
  • Understand why this untapped market warrants pharmaceutical industry interest

    • Table of Contents

    Other users found this report page using the following search terms: back pain pain back pain neuropathic low prevalence painprevalence gabapentin patterns uk referral

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.